Mari Nygård is the head of the research department.
Her research focuses mainly on HPV infection and related cancers, including cervical cancer, and cervical cancer prevention.
Nygård has also focused on the development of personalized cancer prevention and the use of risk- stratified algorithms.
Nygård actively contributes to shape cervical cancer prevention policy. Her efforts in the National expert groups for implementing HPV-based screening in Norway, resulted in policy changes in 2015, when HPV-test started to replace cytology as a primary screening test in Norway.
Nygård is acting as an advisor to the World Health Organization to accelerate Cervical Cancer Elimination activities.
She has also has been consulting with public health policy makers for cervical cancer prevention-related issues in Estonia, Romania, and Ganzu, China. Among the international projects Nygård participates in is a collaboration with the pharmaceutical company MSD where health register data is used to analyze the long-term effect of HPV vaccines.
Finally, Nygård is concerned with utilizing the research opportunities the Norwegian Health infrastructure and registries provide, and is a keen advocate for increased access to biobanks and health registries.
Nygård received her MD from the University of Tartu, Estonia, in 1994, and her PhD in Epidemiology from the University of Tampere, Finland, in 2001.
Her previous work experience includes researcher at the National Public Health Institute in Finland, visiting scientist at Lawrence Livermore National Security, USA, and Visiting Professor at the University of Tartu, Estonia.
Nygård has been affiliated with the Cancer Registry of Norway since 2001.
Biomarkers for HPV
SVEIP – Effect of School Based HPV-Vaccination in the Population
Self-collected specimens in the fight against Cervical Cancer (SESAM)
Fight HPV and cervical cancer
Hvorfor utvikler noen forstadier seg til livmorhalskreft? (Norwegian only)
Screeningatferd og sykdom blant opportunistisk vaksinerte kvinner (Norwegian only)
Kartlegging av medfødte misdannelser hos barn eksponert for Gardasil i fosterlivet (Norwegian only)
Vaksinasjonseffekt: Kjønnsvortetrender i Norge (Norwegian only)
Forebyggende tiltak mot livmorhalskreft: Forbedring av masseundersøkelsen og innvirkning av HPV-vaksine, kvinners livsstil og helse (Norwegian only)
Celleprøve til alle (Norwegian only)
Forbedring av masseundersøkelsen mot livmorhalskreft (Norwegian only)
Regionale forskjeller i livmorhalskreft i Norge (Norwegian only)
Persontilpasset screening mot livmorhalskreft (Norwegian only)
Equalscreen: Økt oppmøte og mindre sosial ulikhet i screening mot livmorhalskreft (Norwegian only)